China
Africa
Explore chapters and articles related to this topic
Nanotechnology-Mediated Radiation Therapy
Published in D. Sakthi Kumar, Aswathy Ravindran Girija, Bionanotechnology in Cancer, 2023
The application of radiation therapy for the treatment of ovarian cancer depends upon the disease stage. Early-stage ovarian cancer can be treated with adjuvant radiation therapy, an advanced stage with consolidated radiation therapy, salvage radiation therapy to treat relapsed cancer, and palliative radiation therapy for metastatic disease. The patient receives a total dosage of 22.5–33 Gy in 10–24 fractions for five-weeks with a booster dose of 40–45 Gy often accompanied by bowel discomfort and vaginal irritation [9].
Overview of Traditional Methods of Diagnosis and Treatment for Women-Associated Cancers
Published in Shazia Rashid, Ankur Saxena, Sabia Rashid, Latest Advances in Diagnosis and Treatment of Women-Associated Cancers, 2022
Malika Ranjan, Namyaa Kumar, Safiya Arfi, Shazia Rashid
Ovarian cancer refers to any cancerous growth that originates in the ovaries, or in related areas of the fallopian tube and the peritoneum. The cause of ovarian cancer is multifactorial which mainly include genetic, immunologic, and environmental factors. Some most common causes of ovarian cancer are inherited gene changes (including BRCA1, BRCA2, BRIP1, RAD51C, RAD51D and genes associated with Lynch syndrome), postmenopausal hormone replacement therapy and endometriosis [16]. The use of oral contraceptives, like birth control pills, has been shown to dramatically reduce the risk of ovarian cancer and endometrial cancer [17].
Cancer
Published in Sally Robinson, Priorities for Health Promotion and Public Health, 2021
Common symptoms of ovarian cancer include bloating, feeling ‘full’ of wind, an increased tummyfrequent urination
Anesthesia management and outcomes of gynecologic oncology surgery
Published in Postgraduate Medicine, 2023
Hicret Yeniay, Bahar Kuvaki, Sule Ozbilgin, Hasan Bahadır Saatli, Hikmet Tunç Timur
A total of 143 patients (34.3%) underwent surgery for ovarian cancer, the 5-year survival rate was 65.7%.). The distribution of cancer stages among patients with ovarian cancer was as follows: stage I, 28.0% (n = 40); stage II, 4.9% (n = 7); stage III, 51.7% (n = 74); and stage IV, 15.4% (n = 22). The five-year survival rates for the different stages of ovarian cancer were as follows: stage I, 95.0% (n = 38); stage II, 71.4% (n = 5); stage III, 55.4% (n = 41); and stage IV, 45.5% (n = 10). In this subgroup, the infused colloid amount was 6744.83 ± 431.10 mL, and a significantly higher amount was administered to the deceased group (p = 0.017). The overall wound site infection rate was 9.1% (n = 13), 5.3% among the surviving patients and 16.3% among the deceased patients; the difference was statistically significant ((OR: 3.47, 95% CI: 1.070–11.269; p = 0.038).
The Prognostic Value of Prognostic Nutritional Index in Patients with Ovarian Cancer: A Systematic Review and Meta-Analysis
Published in Nutrition and Cancer, 2022
Ovarian cancer, one of the most common malignancies in the female reproductive system, is still characterized by high morbidity and mortality worldwide in the recent decades, despite advancements in screening methods, diagnosis, surgery, chemotherapy, radiotherapy, targeted therapy, etc. (1). It is the most lethal gynecological malignant tumor and the fifth most common cause of cancer mortality in women. Of note, ovarian cancer lacks early specific symptoms. As a result, approximately 60% of patients are at advanced stage or have widespread intra-abdominal metastatic disease at initial diagnosis and only 23% of ovarian patients are at early stage (2). To date, primary surgical resection and adjuvant chemotherapy remain the main curative treatment option for patients. However, after treatment, nearly half of the patients will relapse within 16 mo, and about 70% of patients experience recurrence finally (3). The 5-year cancer specific survival rates of ovarian cancer are estimated to be 89% for stage I, 71% for stage II, 41% for stage and only 20% for stage IV patients, respectively (2, 4).
Research Status and Progress of Nutritional Support Therapy for Ovarian Cancer
Published in Nutrition and Cancer, 2022
Yue Wu, Juan Mu, Jian Cao, Dake Li, Yongmei Dai
Ovarian cancer is one of the most common and fatal gynecological tumors (1). In 2020, 313,959 new ovarian cancer cases were diagnosed and 207,252 deaths occurred from ovarian cancer in the world (2). Most of the clinical manifestations of ovarian cancer are not specific and there is no reliable early screening method (3). Patients often seek treatment for malnutrition related symptoms such as abdominal pain, abdominal distension, loss of appetite, nausea, etc. About 75% of patients are reported to be in advanced stage when they seek treatment, which is often accompanied by pelvic and upper abdominal metastasis of the tumor (4). Ovarian cancer is mainly treated by surgery, supplemented by chemotherapy. The surgeon should try his best to remove all visible lesions to ensure that the residual lesions are less than 1 cm (5). Malnutrition leads to vulnerability to infection, intolerance to surgery, and even resistance to chemotherapy (6). The purpose of this review is to summarize how nutritional interventions support treatment for ovarian cancer patients.